Guyasuta Investment Advisors Inc. Sells 11,829 Shares of Pfizer Inc. (NYSE:PFE)

Guyasuta Investment Advisors Inc. trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 8.2% during the fourth quarter, Holdings Channel reports. The institutional investor owned 133,217 shares of the biopharmaceutical company’s stock after selling 11,829 shares during the quarter. Guyasuta Investment Advisors Inc.’s holdings in Pfizer were worth $3,534,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Charles Schwab Investment Management Inc. raised its holdings in shares of Pfizer by 11.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company’s stock valued at $3,766,366,000 after purchasing an additional 12,864,343 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Pfizer by 22.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company’s stock valued at $1,101,713,000 after purchasing an additional 6,977,587 shares during the last quarter. International Assets Investment Management LLC purchased a new stake in shares of Pfizer in the third quarter valued at about $146,481,000. Van ECK Associates Corp raised its holdings in shares of Pfizer by 28.5% in the fourth quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company’s stock valued at $564,739,000 after purchasing an additional 4,726,549 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in shares of Pfizer by 164.2% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,316,405 shares of the biopharmaceutical company’s stock valued at $211,737,000 after purchasing an additional 4,546,809 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.06% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research firms recently issued reports on PFE. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Wolfe Research began coverage on shares of Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective for the company. Citigroup decreased their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, Bank of America restated a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Price Performance

PFE stock opened at $25.50 on Friday. The firm has a 50 day moving average of $26.28 and a 200-day moving average of $27.62. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The firm has a market capitalization of $144.48 billion, a P/E ratio of 18.08, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same period last year, the business earned $0.10 earnings per share. Pfizer’s revenue was up 24.7% compared to the same quarter last year. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 6.75%. Pfizer’s payout ratio is presently 121.99%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.